Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research studies in human beings that follow a pre-defined protocol. We have both interventional & observational types of clinical trials found on this site.
This is a response-adaptive (RAR) prospective randomized study with a long-term follow-up and
the aim of this clinical study is to measure with qualitative and quantitative indicators the
changes in cosmetic results, quality of life and patient satisfaction after delayed-
immediate breast reconstruction with standardized technique Skin Reducing Nipple sparing
mastectomy, SRNSM and SSM with standardized horizontal skin incision.
According to our hypothesis, SRNSM with standardized technique on pendulous/ ptotic breasts
is a safe procedure compared to SSM. It also promotes the cosmetic efficacy of SRNSM with the
removal of the entire glandular tissue through avoidance of the reduction of projection, the
need later nipple reconstruction surgery and of areola tattoo.
In our study we propose that compared to one of the well-known and widely investigated
studied SSM, our current standardized SRNSM technique is able to perform similar
oncologically safe entire gland tissue removal, with low complication rate, accommodating for
adjuvant treatments. Furthermore, it may provide superior cosmetic results than SSM (NAC is
not removed, projection is maintained, and there is no need for further nipple reconstruction
or tattoo) with high patient satisfaction which is maintained long term.
This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.
This randomized, open-label phase 3 study will evaluate the safety and efficacy of Carelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) in combination with Nab-paclitaxel and Apatinib, carelizumab plus nab-paclitaxel, and Nab-paclitaxel in Patients with Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer. Participants will be randomized in a 1:1:1 ratio to Arm A (Carelizumab + Nab-paclitaxel + Apatinib), Arm B (Carelizumab + Nab-paclitaxel), or Arm C (Nab-paclitaxel).